NCT00039416View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

August 31, 2007

Conditions
Chronic Myelomonocytic LeukemiaEssential ThrombocythemiaPolycythemia VeraPrimary Myelofibrosis
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00039416 - Imatinib Mesylate in Treating Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter